VIMRX changes name to Nexell Therapeutics:
This article was originally published in Clinica
Executive Summary
VIMRX Pharmaceuticals is to buy back Baxter's minority interest in its subsidiary, Nexell Therapeutics, and will change its own name to that of the subsidiary, relocating to Nexell's Irvine, California site. Baxter will gain 3 million shares of VIMRX' stock and a seven-year warrant to buy a further 5.2 million shares at $1.15 per share. In addition, the conversion price of the $66 million of stock issued to Baxter in 1997 is to be set at $2.75 per share. Earlier this month, Nexell received an approvable letter from the US FDA for its stem cell preparation system, Isolex (see Clinica No 842, p 15).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.